774 research outputs found
Distance Measures for Dynamic Citation Networks
Acyclic digraphs arise in many natural and artificial processes. Among the
broader set, dynamic citation networks represent a substantively important form
of acyclic digraphs. For example, the study of such networks includes the
spread of ideas through academic citations, the spread of innovation through
patent citations, and the development of precedent in common law systems. The
specific dynamics that produce such acyclic digraphs not only differentiate
them from other classes of graphs, but also provide guidance for the
development of meaningful distance measures. In this article, we develop and
apply our sink distance measure together with the single-linkage hierarchical
clustering algorithm to both a two-dimensional directed preferential attachment
model as well as empirical data drawn from the first quarter century of
decisions of the United States Supreme Court. Despite applying the simplest
combination of distance measures and clustering algorithms, analysis reveals
that more accurate and more interpretable clusterings are produced by this
scheme.Comment: 7 pages, 5 figures. Revision: Added application to the network of the
first quarter-century of Supreme Court citations. Revision 2: Significantly
expanded, includes application on random model as wel
Decoherence and dephasing errors caused by D.C. Stark effect in rapid ion transport
We investigate the error due to D.C. Stark effect for quantum information
processing for trapped ion quantum computers using the scalable architecture
proposed in J. Res. Natl. Inst. Stan. 103, 259 (1998) and Nature 417, 709
(2002). As the operation speed increases, dephasing and decoherence due to the
D.C. Stark effect becomes prominent as a large electric field is applied for
transporting ions rapidly. We estimate the relative significance of the
decoherence and dephasing effects and find that the latter is dominant. We find
that the minimum possible of dephasing is quadratic in the time of flight, and
an inverse cubic in the operational time scale. From these relations, we obtain
the operational speed-range at which the shifts caused by D.C. Stark effect, no
matter follow which trajectory the ion is transported, are no longer
negligible. Without phase correction, the maximum speed a qubit can be
transferred across a 100 micron-long trap, without excessive error, in about 10
ns for Calcium ion and 50 ps for Beryllium ion. In practice, the accumulated
error is difficult to be tracked and calculated, our work gives an estimation
to the range of speed limit imposed by D.C. Stark effect.Comment: 7 pages, 1 figure. v2: Title is changed in this version to make our
argument more focused. Introduction is rewritten. A new section IV is added
to make our point more prominent. v3: Title is changed to make our argument
more specific. Abstract, introduction, and summary are revise
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity
<p>Abstract</p> <p>Background</p> <p>Rapamycin, an inhibitor of mammalian target of Rapamycin (mTOR), is an immunosuppressive agent that has anti-proliferative effects on some tumors. However, the role of Rapamycin-induced immune suppression on tumor progression has not been examined.</p> <p>Methods</p> <p>We developed a transplantation model for generation of mammary tumors in syngeneic recipients that can be used to address the role of the immune system on tumor progression. We examined the effect of Rapamycin on the immune system and growth of MMTV-driven Wnt-1 mammary tumors which were transplanted into irradiated and bone marrow-reconstituted, or naĂŻve mice.</p> <p>Results</p> <p>Rapamycin induced severe immunosuppression and significantly delayed the growth of Wnt-1 tumors. T cell depletion in spleen and thymus and reduction in T cell cytokine secretion were evident within 7 days of therapy. By day 20, splenic but not thymic T cell counts, and cytokine secretion recovered. We determined whether adoptive T cell therapy enhances the anti-cancer effect using <it>ex vivo </it>generated Rapamycin-resistant T cells. However, T cell transfer during Rapamycin therapy did not improve the outcome relative to drug therapy alone. Thus, we could not confirm that suppression of T cell immunity contributes to tumor growth in this model. Consistent with suppression of the mTOR pathway, decreased 4E-BP1, p70 S6-kinase, and S6 protein phosphorylation correlated with a decrease in Wnt-1 tumor cell proliferation.</p> <p>Conclusion</p> <p>Rapamycin has a direct anti-tumor effect on Wnt-1 breast cancer <it>in vivo </it>that involves inhibition of the mTOR pathway at doses that also suppress host immune responses.</p
The depressogenic potential of added dietary sugars
Added sugars are ubiquitous in contemporary Western diets. Although excessive sugar consumption is now
robustly associated with an array of adverse health consequences, comparatively little research has thus far
addressed its impact on the risk of mental illness. But ample evidence suggests that high-dose sugar intake can
perturb numerous metabolic, inflammatory, and neurobiological processes. Many such effects are of particular
relevance to the onset and maintenance of depressive illness, among them: systemic inflammation, gut microbiota
disruption, perturbed dopaminergic reward signaling, insulin resistance, oxidative stress, and the generation
of toxic advanced glycation end-products (AGEs). Accordingly, we hypothesize that added dietary sugars
carry the potential to increase vulnerability to major depressive disorder, particularly at high levels of consumption.
The present paper: (a) summarizes the existing experimental and epidemiological research regarding
sugar consumption and depression vulnerability; (b) examines the impact of sugar ingestion on known depressogenic
physiological processes; and (c) outlines the clinical and theoretical implications of the apparent
sugar-depression link. We conclude that the extant literature supports the hypothesized depressogenic impact of
added dietary sugars, and propose that an improved understanding of the effects of sugar on body and mind may
aid in the development of novel therapeutic and preventative measures for depression
Jumping to Conclusions, a Lack of Belief Flexibility and Delusional Conviction in Psychosis: A Longitudinal Investigation of the Structure, Frequency, and Relatedness of Reasoning Biases
Two reasoning biases, jumping to conclusions (JTC) and belief inflexibility, have been found to be associated with delusions. We examined these biases and their relationship with delusional conviction in a longitudinal cohort of people with schizophrenia-spectrum psychosis. We hypothesized that JTC, lack of belief flexibility, and delusional conviction would form distinct factors, and that JTC and lack of belief flexibility would predict less change in delusional conviction over time. Two hundred seventy-three patients with delusions were assessed over twelve months of a treatment trial (Garety et al., 2008). Forty-one percent of the sample had 100% conviction in their delusions, 50% showed a JTC bias, and 50%â75% showed a lack of belief flexibility. Delusional conviction, JTC, and belief flexibility formed distinct factors although conviction was negatively correlated with belief flexibility. Conviction declined slightly over the year in this established psychosis group, whereas the reasoning biases were stable. There was little evidence that reasoning predicted the slight decline in conviction. The degree to which people believe their delusions, their ability to think that they may be mistaken and to consider alternative explanations, and their hastiness in decision making are three distinct processes although belief flexibility and conviction are related. In this established psychosis sample, reasoning biases changed little in response to medication or psychological therapy. Required now is examination of these processes in psychosis groups where there is greater change in delusion conviction, as well as tests of the effects on delusions when these reasoning biases are specifically targeted
STAT3 Transcription Factor Promotes Instability of nTreg Cells and Limits Generation of iTreg Cells during Acute Murine Graft-versus-Host Disease
SummaryAcute graft-versus-host disease (GvHD) is a major cause of mortality in allogeneic bone marrow transplantation (BMT), for which administration of FoxP3+ regulatory T (Treg) cells has been proposed as a therapy. However, the phenotypic stability of Treg cells is controversial, and STAT3-dependent cytokines can inhibit FoxP3 expression. We assessed whether the elimination of STAT3 in TÂ cells could limit the severity of GvHD. We found STAT3 limited FoxP3+ Treg cell numbers following allogeneic BMT by two pathways: instability of natural Treg (nTreg) cells and inhibition of induced Treg (iTreg) cell polarization from naive CD4+ TÂ cells. Deletion of STAT3 within only the nTreg cell population was not sufficient to protect against lethal GvHD. In contrast, transfer of STAT3-deficient naive CD4+ TÂ cells increased FoxP3+ Treg cells post-BMT and prevented lethality, suggesting that the consequence of STAT3 signaling may be greater for iTreg rather than nTreg cells during GvHD
Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport.
Citalopram prevents serotonin (5-HT) uptake into platelets by blocking the serotonin reuptake transporter (SERT). Although some clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may affect haemostasis and thrombosis, these poorly-characterised effects are not well understood mechanistically and useful in vitro data is limited. We sought to determine whether the inhibitory effects of citalopram on platelets are mediated via its pharmacological inhibition of 5-HT transport. We quantified the inhibitory potency of (RS)-, (R)- and (S)-citalopram on platelet function. If SERT blockade is the primary mechanism for citalopram-mediated platelet inhibition, these potencies should show quantitative congruence with inhibition of 5-HT uptake. Our data show that citalopram inhibits platelet aggregation, adhesion and thromboxane production with no difference in potency between (R)- and (S)-isomers. By contrast, citalopram had a eudysmic ratio of approximately 17 (Sâ>âR) for SERT blockade. Furthermore, nanomolar concentrations of citalopram inhibited 5-HT uptake into platelets but had no effect on other platelet functions, which were inhibited by micromolar concentrations. Our data indicate that citalopram-induced inhibition of platelets in vitro is not mediated by blockade of 5-HT transport. This raises a new question for future investigation: by what mechanism(s) does citalopram inhibit platelets
Autologous, lentivirus-modified, T-rapa cell âmicropharmaciesâ for lysosomal storage disorders
T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin-conditioning ex vivo reprograms T cells, increasing their memory properties and capacity for survival, while reducing inflammatory potential and the amount of preparative conditioning required for engraftment. Rapamycin-conditioned T cells have been tested in patients and deemed to be safe to administer in numerous settings, with reduced occurrence of infusion-related adverse events. We demonstrate that ex vivo lentivirus-modified, rapamycin-conditioned CD4+ T cells can also act as next-generation cellular delivery vehiclesâthat is, âmicropharmaciesââto disseminate corrective enzymes for multiple lysosomal storage disorders. We evaluated the therapeutic potential of this treatment platform for Fabry, Gaucher, Farber, and Pompe diseases in vitro and in vivo. For example, such micropharmacies expressing α-galactosidase A for treatment of Fabry disease were transplanted in mice where they provided functional enzyme in key affected tissues such as kidney and heart, facilitating clearance of pathogenic substrate after a single administration
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas
AbstractReduced-intensity allogeneic hematopoietic stem cell transplantation (alloHSCT), which typically results in mixed chimerism initially after transplantation, has had limited efficacy in chemotherapy-refractory lymphomas. We hypothesized that the rapid establishment of complete donor chimerism would potentiate a graft-versus-lymphoma effect. Fifteen patients with chemotherapy-refractory lymphoma initially received induction with a conventional chemotherapy regimen (etoposide, prednisone, vincristine, cyclophosphamide, adriamycin, fludarabine [EPOCH-F]) to deplete host T cells and provide disease control prior to alloHSCT. Patients then received conditioning with fludarabine and cyclophosphamide followed by alloHSCT from HLA-matched siblings. Graft-versus-host disease prophylaxis consisted of cyclosporine alone. EPOCH-F resulted in 73% of patients having partial responses or stable disease. EPOCH-F depleted host CD4+ T cells from a median of 235 cells/ΌL to 56 cells/ΌL. Fourteen patients underwent alloHSCT, and all had >95% donor engraftment by day 14 after transplantation. The incidence of Grade II to III acute graft-versus-host disease was 71%. There were two therapy-related deaths. There were 8 partial responses and 3 complete responses (CRs) at day 28. Five additional CRs were observed at day 100 without withdrawal of cyclosporine or donor lymphocyte infusion. The rate of CRs for all 15 patients was 60%. The 1-year progression-free survival rate from time of study entry is 67% with only 1 relapse among 9 CRs. At a median potential follow-up of 28 months, the overall survival rate is 53%. These data demonstrate that a potent and durable graft-versus-lymphoma effect can occur against chemotherapy-refractory lymphomas and suggest that this effect may be associated with rapid, complete donor chimerism after reduced-intensity alloHSCT. © 2003 American Society for Blood and Marrow TransplantationBiology of Blood and Marrow Transplantation 9:162-169 (2003
Bostonia: The Boston University Alumni Magazine. Volume 32
Founded in 1900, Bostonia magazine is Boston University's main alumni publication, which covers alumni and student life, as well as university activities, events, and programs
- âŠ